Page 122 - Read Online

Page 14 of 14 Chia et al. Hepatoma Res 2019;5:9 I http://dx.doi.org/10.20517/2394-5079.2018.112

137. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, et al. Case report of a serious adverse event following the administration
of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
138. van den Berg JH, Gomez-Eerland R, van de Wiel B, Hulshoff L, van den Broek D, et al. Case report of a fatal serious adverse event
upon administration of T cells transduced with a MART-1-specific T-cell receptor. Mol Ther 2015;23:1541-50.
139. Gupta S, Bent S, Kohlwes J. Test characteristics of α-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C: A
systematic review and critical analysis. Ann Intern Med 2003;139:46-50.
140. Shaheen KY, Abdel-Mageed AI, Safwat E, AlBreedy AM. The value of serum midkine level in diagnosis of hepatocellular carcinoma.
Int J Hepatol 2015;2015:146389.
141. Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, et al. Clinical validation of combined serological biomarkers for
improved hepatocellular carcinoma diagnosis in 961 patients. Clin Chim Acta 2007;383:147-52.
142. Sun Y, Gao G, Cai J, Wang Y, Qu X, et al. Annexin A2 is a discriminative serological candidate in early hepatocellular carcinoma.
Carcinogenesis 2013;34:595-604.
143. Chounta A, Ellinas C, Tzanetakou V, Pliarhopoulou F, Mplani V, et al. Serum soluble urokinase plasminogen activator receptor as a
screening test for the early diagnosis of hepatocellular carcinoma. Liver Int 2015;35:601-7.